But an Express Scripts spokeswoman said the pricing takes advantage of vulnerable patients who need this and called Catalyst an example of a company misusing the Orphan Drug Act NegativeNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts